Press Releases ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Market Closed - Japan Exchange Other stock markets 07:00:00 16/05/2024 BST			5-day change	1st Jan Change
2,302 ^JPY	-1.67%		+8.74%	+29.04%

2023	Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.	CI
2023	ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ASKA Pharmaceutical : April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries	04-25	PU
ASKA Pharmaceutical : March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication	03-26	PU
ASKA Pharmaceutical : March 21 2024 Newsweek International Features ASKA Pharmaceutical	03-21	PU
ASKA Pharmaceutical : November 13 2023 ASKA Pharmaceutical Featured in a Special Feature in TIME Magazine	11-14	PU
ASKA Pharmaceutical : September 21 2023 ASKA Pharmaceutical Holdings Participates at 2nd Femtech Tokyo	22/09/23	PU
ASKA Pharmaceutical : September 14 2023 Newsweek International Features ASKA Pharmaceutical	14/09/23	PU
ASKA Pharmaceutical : July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)	20/07/23	PU
ASKA Pharmaceutical : June 27 2023 Personnel Changes of Corporate Officers and Board Members of ASKA Pharmaceutical Holdings Subsidiaries	27/06/23	PU
ASKA Pharmaceutical : June 22 2023 ASKA Pharmaceutical Files an Application for Partial Change of Manufacturing and Marketing Approval for RIFXIMA	22/06/23	PU
ASKA Pharmaceutical : June 12 2023 Matters Subject to Measures for Electronic Provision of the Notice of the 2nd Annual General Meeting of Shareholders	11/06/23	PU
ASKA Pharmaceutical : June 12 2023 NOTICE OF CONVOCATION OF THE 2nd ANNUAL GENERAL MEETING OF SHAREHOLDERS	11/06/23	PU
ASKA Pharmaceutical : June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma	09/06/23	PU
ASKA Pharmaceutical : April 24 2023 ASKA Pharmaceutical Enters into a Comprehensive Business Alliance Agreement on Femtech	24/04/23	PU
ASKA Pharmaceutical : April 21 2023 ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities	20/04/23	PU
ASKA Pharmaceutical : April 7 2023 ASKA licensee Hyundai files New Drug Application in Korea for OC Drospirenone	07/04/23	PU
ASKA Pharmaceutical : April 7 2023 ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment	06/04/23	PU
ASKA Pharmaceutical : March 27 2023 Personnel Change of ASKA Pharmaceutical	27/03/23	PU
ASKA Pharmaceutical : March 6 2023 Organizational and Personnel Changes of ASKA Pharmaceutical	05/03/23	PU
ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical® VHH to address an unmet medical need in Obstetrics and Gynecology	07/02/23	PU
ASKA Pharmaceutical : August 26 2022 Organizational and Personnel Changes of ASKA Pharmaceutical	25/08/22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Press Releases

Filters